skip to main content

CRAO Dialysis CV Risk — ESENeph MCQ

Instant feedback + full explanation. One question, done properly.

HardHaemodialysisCRAO Dialysis CV RiskESENeph

Kinpeygo is considered for IgA nephropathy in a patient with Child–Pugh B cirrhosis. Which interpretation of the UK product information is correct?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Use with close monitoring for hypercorticism and adrenal suppression

Explanation lettering: E = shown as B · B = shown as E

B is correct. Kinpeygo is contraindicated in severe hepatic impairment, Child–Pugh C. In Child–Pugh B, systemic availability of oral budesonide was about 3.5-fold higher than in healthy volunteers, so increased glucocorticoid effects and adrenal-axis suppression require monitoring. Targeted release does not abolish hepatic first-pass dependence.

Reference: Kinpeygo 4 mg modified-release hard capsules SmPC: https://www.medicines.org.uk/emc/product/15393/smpc